In today’s highly competitive and rapidly evolving business landscape, having access to accurate and actionable market intelligence has become more important than ever. Organizations across industries are constantly seeking ways to understand changing consumer behavior, track emerging trends, and identify new growth opportunities. Recognizing this critical need, Emergen Research has introduced its latest Biologics Drug Discovery market research content, a comprehensive and insight-driven resource designed to support businesses in making informed and strategic decisions.
The global Biologics Drug Discovery market size is expected to grow from 471.9 billion by the end of 2025 to 1008.1 billion by 2035, registering a revenue CAGR of 8.80% during the forecast period. The major biologics drug discovery market growth factors are adoption of AI-driven antibody design platforms, expansion of synthetic biology in biologic engineering, and technology advancements. The Biologics Drug Discovery market driven by increasing demand for targeted therapies that offer more effective and personalized treatments is propelling the market growth.
Biologics, including monoclonal antibodies, gene therapies, and cell-based therapies, have shown promise in treating a wide range of chronic and complex diseases such as cancer, autoimmune disorders, and genetic conditions. These therapies offer significant advantages over traditional small molecule drugs by targeting specific molecules involved in disease progression, leading to higher efficacy and fewer side effects.
The growing focus on precision medicine, along with advancements in genomics and biotechnology, is driving the demand for biologics, creating a favorable market environment for their discovery and development. For instance, in August 2022, Sanofi partnered with Atomwise in a drug design deal worth potentially up to USD 1.2 billion. The contract, for which Sanofi paid USD 20 million upfront, focused on using the AtomNet platform to research small molecules for up to five drug targets selected by Sanofi.
Additionally, advancements in technology, such as CRISPR gene editing, artificial intelligence (AI), and high-throughput screening, are accelerating the biologics drug discovery process. These technologies enable more efficient identification of novel drug targets, optimization of biologic candidates, and faster clinical trials. AI, in particular, plays a key role in predicting the behavior of biologic molecules, speeding up the drug development timeline and reducing costs.
With increased investment in research and development (R&D) from both public and private sectors, these innovations are fueling market growth, enabling companies to discover new biologic drugs with greater precision and speed. For instance, in February 2025, Variational AI, a Canada-based software company, successfully raised USD 5.5 million in an oversubscribed seed extension round.
One of the most valuable aspects of this research content is its strong focus on delivering practical and actionable recommendations. Rather than simply presenting raw data, the report translates complex information into clear insights that businesses can directly apply to their strategies. Whether a company is looking to expand into new markets, improve its product offerings, or enhance customer engagement, the insights provided in this report can serve as a reliable guide. This approach ensures that the research is not only informative but also results-oriented.
The Biologics Drug Discovery market research content has been developed through a rigorous process that combines advanced analytical techniques with deep industry expertise. Emergen Research’s team of analysts has carefully studied market trends, historical data, and future projections to create a well-rounded and accurate representation of the market. The content includes detailed reports, whitepapers, case studies, and trend analyses, covering a wide range of industries such as healthcare, technology, manufacturing, finance, and consumer goods. This diversity makes the research highly relevant for businesses operating in different sectors.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4927
Another key strength of the report lies in its comprehensive segmentation analysis. The Biologics Drug Discovery market is divided into various segments based on product types, applications, end-user industries, and geographical regions. This level of detail allows businesses to gain a deeper understanding of how different segments are performing and where the most promising opportunities exist. By analyzing demand patterns, production levels, and consumption trends, companies can make more targeted and effective decisions.
The competitive landscape of the biologics drug discovery market is characterized by the presence of large pharmaceutical companies, biotech firms, contract development and manufacturing organizations (CDMOs), and specialized technology providers. Key players such as Pfizer, Roche, Amgen, and Eli Lilly dominate the market with their extensive portfolios of biologic drugs and ongoing research initiatives.
These companies focus on innovations in monoclonal antibodies, gene therapies, and cell-based therapies. Additionally, smaller biotech firms are increasingly playing a role by partnering with large corporations to bring novel biologic drugs to market. Outsourcing to CDMOs is common, as it allows biotech companies to focus on R&D while leveraging the expertise of established manufacturing partners. Technological advancements, particularly in AI and gene-editing tools like CRISPR, also shape competition in this space.
In March 2025, Biogen Inc. received approval from the US Food and Drug Administration (FDA) for TOFIDENCE (tocilizumab-bavi) intravenous formulation. TOFIDENCE marks the pioneering approval of the tocilizumab biosimilar in the United States, signaling a significant advancement in treatment options for specified medical conditions.
Biologics Drug Discovery Market Leaders
- Amgen
- Merck & Co.
- Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb
- Sanofi
- Bayer AG
- AstraZeneca
- GlaxoSmithKline Plc.
- Novartis AG
- Eli Lilly and Company
Competitive landscape:-
The report also provides an in-depth examination of the competitive landscape, which is essential for any business aiming to succeed in a crowded market. It profiles key players in the global Biologics Drug Discovery market and highlights their strategies, recent developments, and market positioning. Information on mergers and acquisitions, partnerships, technological advancements, and product launches helps businesses understand how the competition is evolving. This knowledge can be used to refine strategies and gain a competitive advantage.
Adoption of AI-Driven Antibody Design Platforms drives market growth
The adoption of AI-driven antibody design platforms is driving the biologics drug discovery market by significantly improving the efficiency and accuracy of the antibody development process. Traditional antibody discovery can be time-consuming and resource-intensive, often requiring extensive trial and error in laboratory settings. AI-powered platforms, however, utilize machine learning algorithms and vast biological data sets to predict the most effective antibody candidates.
These platforms can identify optimal binding sites, predict immune responses, and fine-tune antibodies for specific targets, thus accelerating the discovery process. This reduces the time from concept to clinical trials, enabling faster delivery of new biologic therapies to the market and increasing the overall productivity of drug discovery efforts. For instance, in September 2022, a report by the WHO stated that about 55 million people worldwide are living with dementia, and nearly 10 million cases are reported annually.
Furthermore, AI-driven platforms are enhancing the precision of antibody design, allowing for the creation of more targeted and effective therapies. By integrating data from genomics, proteomics, and clinical studies, AI can better understand the complexities of diseases and immune systems.
This helps in designing antibodies that are not only more potent but also more specific, reducing the risk of off-target effects and improving safety profiles. As the demand for personalized medicine continues to rise, these AI platforms are playing a critical role in developing biologic therapies tailored to individual patients, further fueling the growth of the biologics drug discovery market.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/biologics-drug-discovery-market
Beyond competitive analysis, the report is designed to serve a broad audience. It is particularly useful for investors, venture capitalists, startups, and established enterprises that are looking to gain a deeper understanding of the market. Additionally, research organizations, consulting firms, and policymakers can also benefit from the insights provided, using them to support planning, policy development, and strategic initiatives.
-
Type Outlook (Revenue, USD Billion, 2021–2034)
- Blood and Blood Products
- Cellular and Gene Therapy Products
- Tissue and Tissue Products
- Vaccines
- Others Types
-
Indication Outlook (Revenue, USD Billion, 2021–2034)
- Oncology
- Immunology
- Infectiuos Disease
- Other Indications
-
Application Outlook (Revenue, USD Billion, 2021–2034)
- Diagnosis
- Treatment
-
Manufacturing Facility Outlook (Revenue, USD Billion, 2021–2034)
- Outsourced
- In-house
-
Regional Outlook (Revenue, USD Billion, 2021–2034)
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
- North America
One of the defining features of Emergen Research’s content is its commitment to accuracy and relevance. The company ensures that its research is regularly updated to reflect the latest market developments. In a world where trends can change rapidly, having access to up-to-date information is crucial. Businesses that stay informed are better equipped to adapt to changes and seize new opportunities as they arise.
Another important advantage of this research content is the inclusion of expert insights. The analysts behind the report bring years of experience and a deep understanding of industry dynamics. Their ability to interpret data and identify meaningful trends adds significant value to the research. This expert perspective helps businesses not only understand what is happening in the market but also why it is happening, enabling them to make more confident decisions.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4927
Emergen Research’s goal is to simplify complex market information and make it accessible to businesses of all sizes. By presenting data in a clear and structured manner, the company ensures that users can easily understand and apply the insights. This user-friendly approach sets the research apart from traditional reports that often overwhelm readers with excessive data.
About Emergen Research
Emergen Research is a leading market research and consulting firm that specializes in providing high-quality syndicated reports, customized research solutions, and strategic consulting services. The company focuses on helping clients understand market trends, analyze consumer behavior, and identify growth opportunities across multiple industries. With a strong emphasis on delivering fact-based and actionable insights, Emergen Research continues to support businesses in navigating complex market environments and achieving sustainable success.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com